Capital Cell for Companies
Close your investment round faster
Capital Cell is the world's leading alternative investment platform for biotechnology and life sciences companies.
We are an authorized provider under the European Securities and Markets Authority and under the tax incentive schemes in force.
We select the most promising investment opportunities from across Europe to launch on capitalcell.com, helping them find funds in an agile way so they can focus on developing their businesses.
The investment community of Capital Cell
registered
investment
via crowdfunding
media
per investor
How do we do it?
The basic steps for an investment round.
- You share your pitch deck.
- Our BioExpert Network evaluates your company.
- A Lead Investor leads your investment round.
- The Capital Cell committee approves your proposal after passing the analysis.
- Due diligence is completed and the campaign is prepared.
- Start of the pre-campaign for your contacts and our investors.
- Public campaign where we promote it from our website.
- You reach your goal, we close the campaign and you receive the money.
At Capital Cell we work as a team, we only get paid if you win too.
How much does it cost to raise a round of financing with Capital Cell?
Included in the round free of charge
- Analysis and report of the BioExpert Network.
- Crowdfunding consulting and personalized advice.
- Communication and promotion of the campaign among our network of investors.
- Strategic financial consulting: round structure, investment objective, valuation, etc.
- Analysis and report by the consultancy Alira Health.
- Legal and financial due diligence.
- Escrow account and payment gateway.
Not included in the round
Publication on the platform
€750
Crowdfunding campaign:
- Competitive commission on funds raised: 7%.
- At Capital Cell we do not charge commission for previously agreed investments.
Additional services:
- Marketing services : Video, PR (press, events), banners, infographics, advertising on social networks and professional networks : 3% of the campaign target
- Legal services before and after the round: check prices according to your needs
Send us your investment opportunity
Send us your pitch deck and we will evaluate it with our team of experts.
Companies that have already achieved its objectives
Extensive experience of successfully completed rounds. Check our track record.


Bionure - now Accure Therapeutics - raised €1,200,000 in 2017 and €1,337,000 in 2019 to develop an innovative multiple sclerosis drug.


Vytrus went public through an IPO, giving investors a success with its innovative production of plant cell cultures.


GoodGut's diagnostic and therapeutic technology for digestive diseases continues development and commercialization after its sale to HIPRA.